RhumbLine Advisers
AVBP icon

RhumbLine Advisers’s ArriVent BioPharma AVBP Stock Holding History

RhumbLine Advisers’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
46,254
+11,106
+32% +$328K ﹤0.01% 2065
2026
Q1 		$811K Buy
35,148
+3,692
+12% +$83.4K ﹤0.01% 2308
2025
Q4 		$633K Sell
31,456
-2,347
-7% -$48.9K ﹤0.01% 2522
2025
Q3 		$624K Sell
33,803
-151
-0.4% -$2.97K ﹤0.01% 2544
2025
Q2 		$739K Sell
33,954
-3,189
-9% -$66.2K ﹤0.01% 2410
2025
Q1 		$687K Buy
37,143
+453
+1% +$11.1K ﹤0.01% 2360
2024
Q4 		$977K Buy
36,690
+3,069
+9% +$88.1K ﹤0.01% 2261
2024
Q3 		$790K Buy
33,621
+20,914
+165% +$475K ﹤0.01% 2395
2024
Q2 		$236K Buy
12,707
+2,942
+30% +$52.5K ﹤0.01% 3137
2024
Q1 		$174K Buy
+9,765
New +$197K ﹤0.01% 3242

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RhumbLine Advisers's AVBP Position: Q2 2026 in Review

RhumbLine Advisers increased its ArriVent BioPharma (AVBP) stake by 32% in Q2 2026, buying an estimated $328K and bringing the position to 46,254 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

RhumbLine Advisers first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • RhumbLine Advisers held 46,254 shares of ArriVent BioPharma worth $1.61M as of Q2 2026.
  • RhumbLine Advisers bought 11,106 ArriVent BioPharma shares in Q2 2026, an estimated $328K.
  • ArriVent BioPharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2065 holding.
  • RhumbLine Advisers first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.